Jones Heath U, Muhlestein Joseph B, Jones Kent W, Bair Tami L, Lavasani Farangis, Sohrevardi Mahtab, Horne Benjamin D, Doty Donald, Lappe Donald L
Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA.
Circulation. 2002 Sep 24;106(12 Suppl 1):I19-22.
Enoxaparin has become an attractive therapy for use during acute coronary syndrome (ACS) because of its potential superior efficacy over unfractionated heparin (UFH), its longer activity, and its subcutaneous route of administration. However, because a significant number of patients presenting with ACS may be sent directly to open heart surgery while still on anticoagulation, it is important to understand any potential bleeding risks that may be associated with the use of enoxaparin under these circumstances.
From 1998 to 2001, 1159 consecutive patients presenting with an acute coronary syndrome who received either UFH (n=1008) or enoxaparin (n=151) before proceeding to open heart surgery for urgent therapy during the same hospitalization were included in this study. Incidence of perioperative bleeding as evidenced by the units of blood products (packed red blood cells or platelets) transfused or the need for surgical re-exploration for postoperative bleeding was recorded.
Average age was 65+/-11 and 67+/-11 years for patients receiving UFH and enoxaparin, respectively (P=0.005). Seventy-five percent of those receiving UFH and 64% of those receiving enoxaparin (P<0.005) were males. After discharge, the incidence of rehospitalization for hemorrhage requiring return to surgery for re-exploration was 7.9% in the enoxaparin group and 3.7% in the UFH group (adjusted hazard ratio=2.6, P=0.03). The use of blood products did not differ between groups (UFH=2.7+/-6.5 U and enoxaparin=2.3+/-4.5 U; P=NS).
The preoperative use of enoxaparin compared with UFH in patients presenting with an ACS who undergo open-heart surgery during the same hospitalization is associated with a significantly increased incidence of re-exploration for postoperative bleeding. Further study is needed to understand the mechanism of this phenomenon and to develop appropriate guidelines to address this potentially important issue.
依诺肝素因相较于普通肝素(UFH)可能具有更优的疗效、更长的作用时间以及皮下给药途径,已成为急性冠状动脉综合征(ACS)治疗中的一种有吸引力的疗法。然而,由于大量ACS患者在仍接受抗凝治疗时可能直接被送去进行心脏直视手术,了解在这些情况下使用依诺肝素可能存在的任何潜在出血风险很重要。
1998年至2001年,本研究纳入了1159例连续的急性冠状动脉综合征患者,这些患者在同一住院期间接受紧急治疗的心脏直视手术前,分别接受了UFH(n = 1008)或依诺肝素(n = 151)治疗。记录围手术期出血的发生率,以输注的血液制品(浓缩红细胞或血小板)单位数或因术后出血需要再次手术探查来证明。
接受UFH和依诺肝素治疗的患者平均年龄分别为65±11岁和67±11岁(P = 0.005)。接受UFH治疗的患者中有75%为男性,接受依诺肝素治疗的患者中有64%为男性(P<0.005)。出院后,依诺肝素组因出血需要再次手术探查而再次住院的发生率为7.9%,UFH组为3.7%(调整后的风险比=2.6,P = 0.03)。两组之间血液制品的使用无差异(UFH = 2.7±6.5单位,依诺肝素 = 2.3±4.5单位;P = 无显著差异)。
在同一住院期间接受心脏直视手术的ACS患者中,术前使用依诺肝素与UFH相比,术后因出血需要再次探查的发生率显著增加。需要进一步研究以了解这一现象的机制,并制定适当的指南来解决这一潜在的重要问题。